9
Oct
2015

Vertex Takes Heat, Valeant Takes Even More, and Express Scripts Cuts a Deal

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more.

You may also like

Pfizer’s Wager on Small Molecules, Summer IPO Flurries, Gilead’s Protein Degrader Play
Amgen Swings for the RAS Fence, Gilead’s Grilling on Price, & Agios Enlarges the Pie
Thermo Bets on Viral Vector Manufacturing, Precision & Genfit’s IPOs, & Not Much Else
Sage’s Depression Triumph, Biogen’s Alzheimer’s Defeat, & Apple Watch Hype